Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia 1

Interventions

venetoclax 3Imatinib Mesylate 3ponatinib 2nilotinib 2Dasatinib 2Azacitidine 2zileuton 1thymoglobulin 1pulrodemstat besilate 1posaconazole 1emvododstat 1Transplantation 1Standard of Care 1Mycophenolic Acid 1Methylprednisolone Hemisuccinate 1Methylprednisolone Acetate 1Methylprednisolone 1Lenalidomide 1IMC-EB10 1Homoharringtonine 1HhAntag691 1Hematopoietic Stem Cell Transplantation 1Decitabine 1Cytarabine 1Cyclosporine 1CC 401 1BID protein, human 1Antilymphocyte Serum 1AVE9633 13-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myeloid × zileuton × Clear all
NCT02047149 2016-09-30

Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

University of Massachusetts, Worcester

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡